February 26, 2020 / 12:48 PM / in a month

BRIEF-Zynerba Pharmaceuticals Announces The Completion Of Enrollment In The Pivotal Connect-FX Trial Of Zygel In Fragile X Syndrome

Feb 26 (Reuters) - Zynerba Pharmaceuticals Inc:

* ZYNERBA PHARMACEUTICALS ANNOUNCES THE COMPLETION OF ENROLLMENT IN THE PIVOTAL CONNECT-FX TRIAL OF ZYGEL™ IN FRAGILE X SYNDROME

* ZYNERBA PHARMACEUTICALS - TOPLINE RESULTS FROM CONNECT-FX TRIAL EXPECTED LATE IN Q2 OF 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below